Pfizer chooses Lorch as new chairman
This article was originally published in Scrip
Pfizer's board has elected George Lorch, who has served as an independent director since 2000, as its new non-executive chairman. To focus on his new role, Mr Lorch has stepped down from both the company's compensation and science & technology committees. The Pfizer board elected James Kilts as chairman of its compensation committee.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.